ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2007
The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed.
- Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302.International journal of clinical oncology · 2022Trial
- Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study.Thoracic cancer · 2021Trial
- Examined lymph node count and survival in resected non-small cell lung cancer: attenuation of benefit beyond 16 nodes is confined to node-negative disease.Journal of thoracic disease · 2026Article
- Characteristics of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Q787Q Mutation.Annals of surgical oncology · 2025Article
- Analysis of the Effectiveness of a Total Management Model in the Management of Chronic Cough After Lung Cancer Surgery.Thoracic cancer · 2025Article
- Prognostic factors after radical local therapy for oligo-recurrence of non-small cell lung cancer.General thoracic and cardiovascular surgery · 2025Article
- Treatment selection pattern and prognostic factors in older patients with non-small cell lung cancer at recurrence: an observational study.Surgery today · 2025Observational
- Non-Specific Chest Pain-Possibility of Finding Suggestive of Hidden Pleural Metastasis.Respirology case reports · 2025Article
- The TNM classification of lung cancer-a historic perspective.Journal of thoracic disease · 2024Review
- Distant metastasis patterns among lung cancer subtypes and impact of primary tumor resection on survival in metastatic lung cancer using SEER database.Scientific reports · 2024Article
- Evaluation of parietal pleural adhesion and invasion in subpleural lung cancer: value of B-mode ultrasound and contrast-enhanced ultrasound.Quantitative imaging in medicine and surgery · 2024Article
- Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults.BMC cancer · 2023Article
- The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Overview of Challenges and Opportunities in Revising the Nodal Classification of Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023Review
- Examination of the effectiveness of local therapy for oligo-recurrence of EGFR-mutated NSCLC.Thoracic cancer · 2023Article
- Retroviral Replicating Vector Toca 511 (Cancers · 2022Article
- Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015-2017): A multicentre prospective study.The Lancet regional health. Western Pacific · 2022Article
- Th17 cells and their related cytokines: vital players in progression of malignant pleural effusion.Cellular and molecular life sciences : CMLS · 2022Review
- Selection of preoperative stress electrocardiography test for appropriate patients with non-small cell lung cancer.General thoracic and cardiovascular surgery · 2022Article
- Non-Small Cell Lung Cancer with Malignant Pleural Effusion May Require Primary Tumor Radiotherapy in Addition to Drug Treatment.Cancer management and research · 2022Article
- Surgical treatment in malignant pleural effusion.Turk gogus kalp damar cerrahisi dergisi · 2021Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo analyze all nonlymphatic metastatic components (T4 and M1) of the current TNM system of lung cancer, with the objective of providing suggestions for the next edition of the TNM classification for lung cancer. MATERIAL AND
methodsData on 100,809 patients were submitted to the International Association for the Study of Lung Cancer International Database. Of these, 5592 selected T4M0 and M1 patients fulfilled the inclusion criteria for the analysis. Specific categories of clinically staged T4 (lesions not continuous with the primary tumor) and M1 cases were compared with respect to overall survival using Kaplan-Meier survival estimates and comparisons via Cox regression analysis. Relevant findings were validated internally by geographic area and type of database and were validated externally by the North American Surveillance, Epidemiology and End Results Registries.
resultsMedian survival for cT4M0 with malignant pleural effusion was significantly worse than that of other cT4M0 patients (8 months versus 13 months) and was more comparable with M1 cases with metastases to the contralateral lung only (10 months). M1 cases with metastases outside the lung/pleura had a significantly poorer prognosis than those with metastases confined to the lung, with a median survival of 6 months.
conclusionsRevisions to the TNM classification system for lung cancer should include grouping cases with malignant pleural effusions and cases with nodules in the contralateral lung in the M1a category, and cases with distant metastases should be designated M1b. In addition, cases with nodule(s) in the ipsilateral lung (nonprimary lobe), currently staged M1, should be reclassified as T4M0, in accordance with the recommendations of the T descriptor subcommittee of the IASLC international staging committee.
Indexed as
Identifiers
17762334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.